Sign up to our newsletter
and receive exclusive information and discount coupons straight to your inbox

Top news by writer

Daniel Tomas
Tehnology Writer

HEALTH / The daily deal : a neck massager at an unbeatable price
As of this week, helpmeoutDOC has begun offering a series of massively discounted health items for sale. Today it is time to introduce our readers…
July 28, 2016 | 0 comments

Gabriel Rosoga
Medical and Health Writer

BEAUTY & SKIN CARE / Bee venom serums work miracles on skin
Bee venom, when used in small dosis, proves to be a very effective natural medicine, with extremely beneficial impact on the human organism, with particular…
September 8, 2016 | 1 comment

Ion Gireada
Science Writer

HEALTH / Reasons why your brain hears a ringing
Brain activity in people affected by tinnitus is very different from what happens when sound is detected in brains of healthy people, new research uncovered.…
April 27, 2015 | 0 comments

Ionut Popescu
Health and lifestyle writer

HEALTH / Brits oblivious to obesity leading to cancer
British population largely unware of link between obesity and cancer, finds new survey conducted by the organization Cancer Research UK. According to the survey, 75%…
September 9, 2016 | 0 comments

New drug gets FDA’s approval for battling pediatric cancer

by Ion Gireada on 12 March 2015
Health, Lifestyle, Medical technology     |      dinutuximab,  immature nerve cells,  neuroblastoma,  Unituxin

The Food and Drug Administration said it approved United Therapeutics Corp’s drug to treat neuroblastoma, a rare cancer that typically occurs in children below 5 years.

Unituxin is the first drug approved to treat high-risk neuroblastoma patients who have a greater chance of tumors recurring or progressing after chemotherapy. Patients with high-risk neuroblastoma have only a 40 to 50 percent chance of long-term survival despite aggressive treatment.

There are an estimated 650 cases of neuroblastoma diagnosed in the United States each year. The disease, slightly more common in boys, forms from immature nerve cells.

The FDA approved the drug Unituxin (dinutuximab) as part of a combined treatment regimen — including surgery, chemotherapy and radiation therapy — for patients who had at least a partial response to a previous combined treatment program.

“Unituxin fulfills a critical need by providing a treatment option that prolongs survival in children with high-risk neuroblastoma,” Dr. Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, said in an agency news release.

Unituxin, a combination of mouse and human DNA, is an antibody that sticks to the surface of the cancer-affected cells and uses the body’s immune system to destroy the cells.

The safety and effectiveness of the drug were tested in a clinical trial comprising 226 patients. After three years of treatment, 63 percent of those receiving the drug were alive and free of tumor growth.

Unituxin can now be used to battle the a rare form of cancer that forms from immature nerve cells. Dr. John Maris, professor of pediatric oncology at the Children’s Hospital of Philadelphia, says until now, doctors battled the cancer with surgery, radiation and chemotherapy and this gives them a major addition to the arsenal:

“Unituxin is a new therapy that tricks the body into recognizing the cancer has foreign and attacks it with the tools of the child’s own immune system, ” said Dr. John Maris, professor of pediatric oncology at the Children’s Hospital of Philadelphia.

New drug gets FDA’s approval for battling pediatric cancer

facebook pinterest google+